Video Reports

The big impact of MEK inhibitors has been 2-fold. One is that it delays resistance, which you know, you have this additional blockade for cells that have somehow managed to live without BRAF.

Jeffrey S. Weber, MD, PhD: There’s a whole raft of phase III trials that will come to mature—SD-101, CMP-001, the MASTERKEY-265—and then there’s the NKTR-nivolumab trial.

Sanjiv S. Agarwala, MD: The metastatic melanoma has similar issues and discussions.

Sanjiv S. Agarwala, MD: Perfect segue to talk about the resistant patients.